Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort
Autor: | Sophie de Guibert, Lauren Veronese, Loic Ysebaert, Charles Herbaux, Olivier Tournilhac, Emmanuelle Tchernonog, Anne-Sophie Michallet, Florence Cymbalista, Damien Roos-Weil, Bruno Pereira, Jehan Dupuis, Pierre Feugier, Anne Calleja, Florian Bouclet, Caroline Dartigeas, Sandy Amorim, Anaise Blouet, Marie-Sarah Dilhuydy, Florence Nguyen-Khac, Pierre Morel, Nataliya Dmytruck, Kamel Laribi, Alain Delmer, Thérèse Aurran, Bénédicte Hivert, Romain Guieze |
---|---|
Přispěvatelé: | Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne (UCA), FAYE, Fatimata |
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
Oncology
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology Compassionate Use Trials Male medicine.medical_treatment Chronic lymphocytic leukemia Abnormal Karyotype Kaplan-Meier Estimate Targeted therapy law.invention chemistry.chemical_compound 0302 clinical medicine Randomized controlled trial law Medicine ComputingMilieux_MISCELLANEOUS Aged 80 and over Sulfonamides Hematology Hematopoietic Stem Cell Transplantation [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology General Medicine Middle Aged Progression-Free Survival 3. Good health Tumor lysis syndrome Treatment Outcome 030220 oncology & carcinogenesis Cohort Female France Lymphoma Large B-Cell Diffuse Adult medicine.medical_specialty Antineoplastic Agents Infections 03 medical and health sciences Internal medicine Complex Karyotype Humans Aged Retrospective Studies business.industry Venetoclax medicine.disease Bridged Bicyclo Compounds Heterocyclic Genes p53 Leukemia Lymphocytic Chronic B-Cell chemistry Drug Evaluation business Tumor Lysis Syndrome 030215 immunology |
Zdroj: | Annals of Hematology Annals of Hematology, Springer Verlag, 2021, 100 (4), pp.987-993. ⟨10.1007/s00277-021-04419-w⟩ |
ISSN: | 0939-5555 1432-0584 |
Popis: | The BCL2 inhibitor venetoclax is transforming the management of patients with chronic lymphocytic leukemia (CLL), given its high efficacy in relapsed/refractory CLL as observed in both early-phase and randomized clinical trials. The present study aimed to determine whether venetoclax is effective and well tolerated in patients with CLL or Richter's syndrome (RS) in a real-world setting and to highlight factors impacting survival. Data from a venetoclax French compassionate use program were collected for 67 patients (60 with CLL and 7 with RS). Most patients presented adverse genetic features, such as TP53 disruption (74%) or complex karyotype (58%). Tumor lysis syndrome was observed in 14 (22%) patients, and 16 (24%) patients were hospitalized for grade III/IV infection. In the CLL cohort, ORR was 75 %, 1-year PFS was 61% (95% CI = 47-72%) and 1-year OS 70% (95% CI = 56-80%). No impact of TP53 disruption was noted while complex karyotype was identified as a predictor of both inferior PFS (HR = 3.46; 95% CI = 1-12; log-rank p = 0.03) and OS (HR = 3.2; 95% CI = 0.9-11.4, log-rank p = 0.047). Among the seven patients with RS, two achieved an objective response to venetoclax; however, the median OS was only 1.1 month. The well-balanced safety/efficacy profile of venetoclax is confirmed in this real-world setting. Complex karyotype should be evaluated as a predictive factor of survival for patients treated by venetoclax. |
Databáze: | OpenAIRE |
Externí odkaz: |